Quick Answer
InMed Pharmaceuticals Inc. reported Diluted EPS of $8.36 per share (loss) for fiscal year 2025.
InMed Pharmaceuticals Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.36 | +58.5% |
| 2024 | -$20.14 | -519.7% |
| 2023 | -$3.25 | +90.2% |
| 2022 | -$33.17 | +12.6% |
| 2021 | -$37.96 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.51 | +86.0% | -15.9% |
| September 30, 2025 | -$0.44 | +83.8% | +77.3% |
| March 31, 2025 | -$1.94 | +45.8% | +46.7% |
| December 31, 2024 | -$3.64 | +1.9% | -34.3% |
| September 30, 2024 | -$2.71 | +82.2% | +24.3% |
| March 31, 2024 | -$3.58 | -496.7% | +3.5% |
| December 31, 2023 | -$3.71 | -307.7% | +75.7% |
| September 30, 2023 | -$15.24 | -275.4% | -2440.0% |
- InMed Pharmaceuticals Inc. showed an increase of +58.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, InMed Pharmaceuticals Inc.’s diluted eps has grown by 78.0% (from $37.96 per share (loss) to $8.36 per share (loss)).
- The most recent figure is from InMed Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: